Comparative Pharmacology
Head-to-head clinical analysis: CEFADROXIL versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADROXIL versus DURICEF.
CEFADROXIL vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g orally once daily or divided into two doses every 12 hours.
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life 1.1-1.5 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefadroxil + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefadroxil."
Clinical Note
moderateCefadroxil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil."
Clinical Note
moderateWarfarin + Cefadroxil
"Warfarin may increase the anticoagulant activities of Cefadroxil."
Clinical Note
moderatePhenprocoumon + Cefadroxil
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<5%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefadroxil."